Next Generation Biopharmaceuticals: Product Development

  • Roman MathaesEmail author
  • Hanns-Christian Mahler
Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 165)


Therapeutic proteins show a rapid market growth. The relatively young biotech industry already represents 20 % of the total global pharma market. The biotech industry environment has traditionally been fast-pasted and intellectually stimulated. Nowadays the top ten best selling drugs are dominated by monoclonal antibodies (mABs).

Despite mABs being the biggest medical breakthrough in the last 25 years, technical innovation does not stand still.

The goal remains to preserve the benefits of a conventional mAB (serum half-life and specificity) whilst further improving efficacy and safety and to open new and better avenues for treating patients, e.g., improving the potency of molecules, target binding, tissue penetration, tailored pharmacokinetics, and reduced adverse effects or immunogenicity.

The next generation of biopharmaceuticals can pose specific chemistry, manufacturing, and control (CMC) challenges. In contrast to conventional proteins, next-generation biopharmaceuticals often require lyophilization of the final drug product to ensure storage stability over shelf-life time. In addition, next-generation biopharmaceuticals require analytical methods that cover different ways of possible degradation patterns and pathways, and product development is a long way from being straight forward. The element of “prior knowledge” does not exist equally for most novel formats compared to antibodies, and thus the assessment of critical quality attributes (CQAs) and the definition of CQA assessment criteria and specifications is difficult, especially in early-stage development.


Antibodies Chemistry, manufacturing, and control (CMC) Drug product development Next-generation antibody formats 


  1. 1.
    Miller KL, Lanthier M (2015) Regulatory watch: innovation in biologic new molecular entities: 1986-2014. Nat Rev Drug Discov 14(2):83–83PubMedGoogle Scholar
  2. 2.
    Elvin JG, Couston RG, van der Walle CF (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 440(1):83–98PubMedGoogle Scholar
  3. 3.
    Milstein C (1999) The hybridoma revolution: an offshoot of basic research. Bioessays 21(11):966–973PubMedGoogle Scholar
  4. 4.
    Smith GP, Petrenko VA (1997) Phage display. Chem Rev 97(2):391–410PubMedGoogle Scholar
  5. 5.
    Riechmann L et al (1988) Reshaping human antibodies for therapy. Nature 332(6162):323–327PubMedCentralPubMedGoogle Scholar
  6. 6.
    Story CM (1994) A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 180(6):2377–2381PubMedGoogle Scholar
  7. 7.
    Jakovljevic MB (2014) Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health Econ Ther Pathways 15(1):27–32Google Scholar
  8. 8.
    Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317(9):1261–1269PubMedGoogle Scholar
  9. 9.
    Saag KG et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 59(6):762–784Google Scholar
  10. 10.
    Singh JA et al (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J 128(5):309–310PubMedGoogle Scholar
  11. 11.
    Udpa N, Million RP (2015) Monoclonal antibody biosimilars. Nat Rev Drug Discov 15:13PubMedGoogle Scholar
  12. 12.
    Zolot RS, Basu S, Million RP (2013) Antibody–drug conjugates. Nat Rev Drug Discov 12(4):259–260PubMedGoogle Scholar
  13. 13.
    Ornes S (2013) Antibody–drug conjugates. Proc Natl Acad Sci U S A 110(34):13695–13695PubMedCentralPubMedGoogle Scholar
  14. 14.
    Alley SC, Okeley NM, Senter PD (2010) Antibody–drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529–537PubMedGoogle Scholar
  15. 15.
    Jain N et al (2015) Current ADC linker chemistry. Pharm Res 32(11):3526–3540PubMedCentralPubMedGoogle Scholar
  16. 16.
    Le LN et al (2012) Profiling antibody drug conjugate positional isomers: a system-of-equations approach. Anal Chem 84(17):7479–7486PubMedGoogle Scholar
  17. 17.
    Beckley NS et al (2013) Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem 24(10):1674–1683PubMedGoogle Scholar
  18. 18.
    Singh SK, Luisi DL, Pak RH (2015) Antibody-drug conjugates: design, formulation and physicochemical stability. Pharm Res 32(11):3541–3571PubMedGoogle Scholar
  19. 19.
    Junutula JR et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925–932PubMedGoogle Scholar
  20. 20.
    Shen B-Q et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30(2):184–189PubMedGoogle Scholar
  21. 21.
    Axup JY et al (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 109(40):16101–16106PubMedCentralPubMedGoogle Scholar
  22. 22.
    Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7):631–637PubMedGoogle Scholar
  23. 23.
    Younes A, Yasothan U, Kirkpatrick P (2012) Brentuximab vedotin. Nat Rev Drug Discov 11(1):19–20PubMedGoogle Scholar
  24. 24.
    Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17(20):6417–6427PubMedGoogle Scholar
  25. 25.
    Kim MT et al (2014) Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjug Chem 25(7):1223–1232PubMedGoogle Scholar
  26. 26.
    Chowdhury R, Ellis P (2014) Trastuzumab (Herceptin®) and Ado‐Trastuzumab Emtansine (Kadcyla®): treatments for HER2‐positive breast cancer. In: Handbook of therapeutic antibodies, pp 2041–2068Google Scholar
  27. 27.
    Cartwright H (2011) BMS/Ambrx deal highlights big pharma’s growing interest in protein drug engineering. PharmaDeals Rev 2011(10):1756Google Scholar
  28. 28.
    Agarwal P et al (2013) Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem 24(6):846–851PubMedGoogle Scholar
  29. 29.
    Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3:415PubMedCentralPubMedGoogle Scholar
  30. 30.
    Czajkowsky DM et al (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4(10):1015–1028PubMedCentralPubMedGoogle Scholar
  31. 31.
    Kienast Y et al (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19(24):6730–6740PubMedGoogle Scholar
  32. 32.
    Heier JS et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548PubMedGoogle Scholar
  33. 33.
    Matthews JE et al (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metabol 93(12):4810–4817Google Scholar
  34. 34.
    Herrington-Symes AP et al (2013) Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol 4:689Google Scholar
  35. 35.
    Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136PubMedGoogle Scholar
  36. 36.
    Manning MC et al (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27(4):544–575PubMedGoogle Scholar
  37. 37.
    Wang W et al (2007) Antibody structure, instability, and formulation. J Pharm Sci 96(1):1–26PubMedGoogle Scholar
  38. 38.
    Mahler HC et al (2009) Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 98(9):2909–2934PubMedGoogle Scholar
  39. 39.
    Harris RJ et al (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752(2):233–245PubMedGoogle Scholar
  40. 40.
    Mahler HC et al (2010) Protein aggregation and particle formation: effects of formulation, interfaces, and drug product manufacturing operations. Aggregation Ther Proteins:301–331Google Scholar
  41. 41.
    Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100(2):354–387PubMedGoogle Scholar
  42. 42.
    Chi E et al (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325–1336PubMedGoogle Scholar
  43. 43.
    Singh SK et al (2010) An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99(8):3302–3321PubMedGoogle Scholar
  44. 44.
    Mahler HC, Borchard G, Luessen HL (eds) (2010) Protein pharmaceuticals: formulation, analytics and delivery. ECV-Editio Cantor-Verlag, MainzGoogle Scholar
  45. 45.
    Jarasch A et al (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104(6):1885–1898PubMedGoogle Scholar
  46. 46.
    Pikal MJ (2002) Freeze drying. Encyclopedia of Pharmaceutical Technology, Marcel Dekker, New York. 1299, p 1326Google Scholar
  47. 47.
    Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129–188PubMedGoogle Scholar
  48. 48.
    Haag R (2004) Supramolecular drug-delivery systems based on polymeric core–shell architectures. Angew Chem Int Ed Engl 43(3):278–282PubMedGoogle Scholar
  49. 49.
    Leriche G, Chisholm L, Wagner A (2012) Cleavable linkers in chemical biology. Bioorg Med Chem 20(2):571–582PubMedGoogle Scholar
  50. 50.
    Ouyang J (2013) Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Methods Mol Biol 1045:275–283PubMedGoogle Scholar
  51. 51.
    Pikal MJ, Shah S (1990) The collapse temperature in freeze drying: dependence on measurement methodology and rate of water removal from the glassy phase. Int J Pharm 62(2):165–186Google Scholar
  52. 52.
    Roy M et al (1991) The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory. Dev Biol Stand 74:323–339 discussion 340Google Scholar
  53. 53.
    Tang XC, Pikal MJ (2004) Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res 21(2):191–200PubMedGoogle Scholar
  54. 54.
    Murase N, Franks F (1989) Salt precipitation during the freeze-concentration of phosphate buffer solutions. Biophys Chem 34(3):293–300PubMedGoogle Scholar
  55. 55.
    Bhatnagar BS, Bogner RH, Pikal MJ (2007) Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12(5):505–523PubMedCentralPubMedGoogle Scholar
  56. 56.
    Rambhatla S et al (2004) Heat and mass transfer scale-up issues during freeze drying: II. Control and characterization of the degree of supercooling. AAPS PharmSciTech 5(4):54–62PubMedCentralPubMedGoogle Scholar
  57. 57.
    Geidobler R, Winter G (2013) Controlled ice nucleation in the field of freeze-drying: Fundamentals and technology review. Eur J Pharm Biopharm 85(2):214–222PubMedGoogle Scholar
  58. 58.
    Fissore D, Pisano R, Barresi AA (2011) Advanced approach to build the design space for the primary drying of a pharmaceutical freeze-drying process. J Pharm Sci 100(11):4922–4933PubMedGoogle Scholar
  59. 59.
    Pikal M (1985) Use of laboratory data in freeze drying process design: heat and mass transfer coefficients and the computer simulation of freeze drying. PDA J Pharm Sci Technol 39(3):115–139Google Scholar
  60. 60.
    Schneid SC et al (2015) Application of process analytical technology for monitoring freeze-drying of an amorphous protein formulation: use of complementary tools for real-time product temperature measurements and endpoint detection. J Pharm Sci 104(5):1741–1749PubMedGoogle Scholar
  61. 61.
    Schneid SC et al (2011) Optimization of the secondary drying step in freeze drying using TDLAS technology. AAPS PharmSciTech 12(1):379–387PubMedCentralPubMedGoogle Scholar
  62. 62.
    Pikal M et al (1990) The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int J Pharm 60(3):203–207Google Scholar
  63. 63.
    Carpenter JF et al (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 14(8):969–975PubMedGoogle Scholar
  64. 64.
    Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203(1):1–60PubMedGoogle Scholar
  65. 65.
    Franks F (1998) Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm 45(3):221–229PubMedGoogle Scholar
  66. 66.
    Prestrelski SJ et al (1993) Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65(2):661–671PubMedCentralPubMedGoogle Scholar
  67. 67.
    Kolhe P, Amend E, Singh SK (2010) Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol Prog 26(3):727–733PubMedGoogle Scholar
  68. 68.
    Yu A et al (1998) Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int J Artif Organs 21(6):341–343PubMedGoogle Scholar
  69. 69.
    Carpenter J, Prestrelski S, Arakawa T (1993) Separation of freezing-and drying-induced denaturation of lyophilized proteins using stress-specific stabilization: I. Enzyme activity and calorimetric studies. Arch Biochem Biophys 303(2):456–464PubMedGoogle Scholar
  70. 70.
    Glomb MA, Monnier VM (1995) Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270(17):10017–10026PubMedGoogle Scholar
  71. 71.
    Chang BS, Kendrick BS, Carpenter JF (1996) Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85(12):1325–1330PubMedGoogle Scholar
  72. 72.
    Hawe A et al (2009) Structural properties of monoclonal antibody aggregates induced by freeze–thawing and thermal stress. Eur J Pharm Sci 38(2):79–87PubMedGoogle Scholar
  73. 73.
    Pikal-Cleland KA et al (2000) Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric β-galactosidase. Arch Biochem Biophys 384(2):398–406PubMedGoogle Scholar
  74. 74.
    Singh SK et al (2011) Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res 28(4):873–885PubMedGoogle Scholar
  75. 75.
    Gikanga B et al (2015) Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality. PDA J Pharm Sci Technol 69(2):284–296PubMedGoogle Scholar
  76. 76.
    Allmendinger A et al (2015) Sterile filtration of highly concentrated protein formulations: impact of protein concentration, formulation composition, and filter material. J Pharm Sci 104:3319–3329PubMedGoogle Scholar
  77. 77.
    Tyagi AK et al (2009) IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98(1):94–104PubMedGoogle Scholar
  78. 78.
    Shieu W, Stauch OB, Maa Y-F (2015) Filling of high-concentration monoclonal antibody formulations into pre-filled syringes: investigating formulation-nozzle interactions to minimize nozzle clogging. PDA J Pharm Sci Technol 69(3):417–426PubMedGoogle Scholar
  79. 79.
    Shieu W et al (2014) Filling of high-concentration monoclonal antibody formulations into pre-filled syringes: filling parameter investigation and optimization. PDA J Pharm Sci Technol 68(2):153–163PubMedGoogle Scholar
  80. 80.
    Torosantucci R et al (2013) Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon beta-1a: potential implications for protein aggregation and immunogenicity. Mol Pharm 10(6):2311–2322PubMedCentralPubMedGoogle Scholar
  81. 81.
    Kishore RS et al (2011) The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics. Pharm Res 28(5):1194–1210PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Drug Product Services, Lonza AGBaselSwitzerland

Personalised recommendations